RenovoRx, Inc.
RNXTAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Aug 28, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 1, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2026 |
| Ascendiant Capital | maintain | Buy | Feb 17, 2026 |
| Ascendiant Capital | maintain | Buy | Nov 21, 2025 |
| Ascendiant Capital | maintain | Buy | Aug 25, 2025 |
| Ascendiant Capital | maintain | Buy | Jun 5, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 19, 2025 |
| Ascendiant Capital | maintain | Buy | Apr 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| Ascendiant Capital | maintain | Buy | Dec 10, 2024 |
| Ascendiant Capital | maintain | Buy | Sep 12, 2024 |
| Maxim Group | downgrade | Buy →Hold | Nov 15, 2023 |
| Roth MKM | maintain | Buy | Aug 18, 2023 |
| Roth Capital | maintain | Buy | Nov 1, 2021 |
| Maxim Group | maintain | Buy | Oct 6, 2021 |
Earnings History
Next report: Mar 29, 2027 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.07 | $-0.06 | $1.1M | $1.1M |
| Aug 12, 2026 | $-0.05 | $-0.07 | $909.0K | $703.8K |
| May 14, 2026 | $-0.08 | $-0.08 | $563.0K | $469.5K |
| Mar 30, 2026 | $-0.08 | $-0.08 | $238.0K | $419.7K |
| Nov 13, 2025 | $-0.08 | $-0.08 | $266.0K | $405.4K |
| Aug 14, 2025 | $-0.08 | $-0.08 | $422.0K | $304.0K |
| May 15, 2025 | $-0.08 | $-0.08 | $197.0K | $183.3K |
| Mar 31, 2025 | $-0.12 | $-0.13 | $43.0K | $167.5K |
News
RenovoRx NASDAQ: RNXT reported record third-quarter 2026 revenue of $1.07 million, exceeding $1 million in quarterly sales for the first time as more cancer centers adopted its RenovoCath drug-delivery device.
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP Beyond Locally Advanced Pancreatic Cancer, Signaling Potential for Broader Clinical Adoption Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.
MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, are scheduled to present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum being held on Novemb…
MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026.
University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection
Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC
RenovoRx, Inc. (NASDAQ: RNXT - Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 673,558 shares, a growth of 55.7% from the August 31st total of 432,726 shares. Based on an average trading volume of 2,055,813 shares, the days-to-cover ratio is
MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C.
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleare…
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasda…
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath
RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading.
RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.
MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, is pleased to announce completion of enrollment in the Company's Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).